3:16 PM
 | 
May 24, 2018
 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline.

Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor (KPT-8602) in China and Macau for cancer. Both are oral selective inhibitors of nuclear export (SINE) protein exportin 1 (XPO1; CRM1). Antengene also gains development and commercial rights in China, Macau, Taiwan, Hong Kong, South Korea and ASEAN countries to verdinexor (KPT-335) for non-cancer indications and KPT-9274 for cancer.

Verdinexor is an...

Read the full 416 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >